ÂÜÀòÂÒÂ×

Richard Jones, Ph.D. has extensive experience in translational therapeutic oncology and the development of novel chemotherapeutic treatments for lymphoid malignancies. Richard co-founded a biotechnology company focused on immune modulating therapies for cancer, autoimmune, and infectious diseases. In their role as Director of Translational Biology at Asylia Therapeutics, Inc., they are instrumental in the generation of humanized antibody clones and the advancement of the drug pipeline. Prior to this, Dr. Jones held positions at MD Anderson Cancer Center where they conducted research on the potential therapeutic applications of HDM-2 inhibitors for hematologic malignancies. Richard has also investigated the role of Epstein-Barr virus in cancer development and therapeutic strategies to counter its oncogenic potential. Dr. Jones completed their post-doctoral fellowship at the University of North Carolina at Chapel Hill where they focused on viral and translational therapeutic oncology.

Richard Jones, Ph.D. has a Doctor of Philosophy (Ph.D.) degree in Oncology and Cancer Biology from the University of Birmingham. Richard obtained this degree at an unspecified time. Prior to that, they completed their Bachelor of Science (B.Sc.) in Biomedical Science at the University of Wolverhampton, although the specific dates of their undergraduate education are not provided.